STOCK TITAN

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CORAL GABLES, Fla., May 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate at two upcoming conferences. The management team will also host one-on-one investor meetings at the conferences.

Presentation Details:

Event:  H.C. Wainwright Global Investment Conference
Date:  May 24, 2022
Time:  4:00 PM Eastern Time

Event:  Jefferies Healthcare Conference
Date:  June 8, 2022
Time:  11:00 AM Eastern Time

The webcast will be available on the Company's website, and a replay will be accessible for at least 14 days.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a commercial stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.

For additional information about the Company, please visit www.catalystpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2021 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals

Investor Relations Contact:

Mary Coleman
Catalyst Pharmaceuticals
(305) 420-3200
mcoleman@catalystpharma.com

Media Contact:

David Schull
Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com


Catalyst Pharmaceuticals Inc

NASDAQ:CPRX

CPRX Rankings

CPRX Latest News

CPRX Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Coral Gables

About CPRX

catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso